Ellence
Ellence (epirubicin hydrochloride) is an anthracycline cytotoxic drug (chemotherapy) indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. It works by interfering with DNA and RNA synthesis in rapidly dividing cancer cells.
Dosage by Body Weight
Administered exclusively intravenously. The recommended starting dose is 100 to 120 mg/m² given in repeated 3- to 4-week cycles. Dosage is strictly calculated based on Body Surface Area (BSA) and individual patient clinical status (including liver, renal, and cardiac function), rather than body weight alone. Not for self-administration.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. Dosing is strictly calculated by Body Surface Area (BSA) in adults.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. Dosing is strictly calculated by Body Surface Area (BSA) in adults. |
| 5-7 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 8-10 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 11-15 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 16-20 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
Formulation
Purpose
Adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Generic Name
Epirubicin hydrochlorideScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.